Evaluation of NGS Whole Genome Sequencing Technology in Assisted Reproduction in Georgia

Georgia NGS Whole Genome Sequencing Technology: Practical Value and Considerations in Assisted Reproduction

1. The Logic Doctors Refer to When Making Decisions

In reproductive centers in Georgia, when doctors decide whether to recommend NGS whole genome sequencing, they primarily rely on three variables: patient age, history of previous embryonic chromosomal abnormalities, and known carrier status for single-gene genetic disorders. NGS whole genome sequencing differs from conventional PGT-A (chromosomal aneuploidy screening) — it can not only detect numerical abnormalities of the 23 pairs of chromosomes but also cover microdeletions, microduplications, and even single-gene point mutations (such as cystic fibrosis, thalassemia, etc.). However, doctors also assess: the cost of whole genome sequencing, the testing turnaround time (usually requiring an additional 3-5 days, affecting the fresh cycle transfer window), and the potential for uncertain results (such as variants of uncertain significance, VOUS).

2. Direct Answer: How Good is Georgia's NGS Whole Genome Sequencing Technology?

Technically, Georgia's NGS whole genome sequencing services have largely aligned with international mainstream standards (such as those in the USA and Europe). Some local reproductive centers have introduced sequencing platforms from Illumina or MGI Tech and equipped independent embryology laboratories. Its core performance indicators include:

• Sensitivity for detecting chromosomal numerical abnormalities: >99%
• Resolution for detecting copy number variations (CNVs): Can reach 100kb to 1Mb (superior to the 1-2Mb of traditional aCGH)
• Ability to detect mosaicism: Can identify mosaic ratios above 10%
• Single-gene disease detection: Requires prior library preparation and family validation; not a routine default item in whole genome sequencing

However, it is important to note: Georgia currently lacks unified industry quality control standards. Differences exist between reproductive centers in experimental procedures, timing of embryo biopsy (Day 5 blastocyst trophectoderm biopsy vs. Day 3 cleavage stage biopsy), and data analysis algorithms, leading to inconsistent result stability.

3. Why Do Some People Choose Georgia for NGS Whole Genome Sequencing?

The main competitive advantage of undergoing NGS whole genome sequencing in Georgia is the relatively lower cost (approximately 30% to 50% of the cost in the USA), and the ability to apply without absolute genetic indications. For couples over 35 years old, with a history of repeated implantation failure, or who have previously given birth to a child with chromosomal abnormalities, NGS whole genome sequencing can provide more comprehensive information than conventional PGT-A. Additionally, Georgian law permits full chromosome screening of embryos and does not restrict embryo sex selection (ethically controversial, but technically feasible), which is also a reason for some clients to choose this option.

4. The Easiest Detail to Overlook: NGS Whole Genome Sequencing ≠ 100% Accurate

In clinical decision-making, the following details are easily overlooked:

5. The Easiest Pitfall: Treating Whole Genome Sequencing as a Universal Screening Tool

Some users mistakenly believe that "whole genome sequencing" can screen for all genetic diseases. In reality:

• Routine NGS whole genome sequencing typically only analyzes cells from the trophectoderm of the embryo, not the infant itself; it is merely a screening tool before embryo implantation and cannot detect complex polygenic diseases that may manifest after birth (e.g., diabetes, schizophrenia).
• For known single-gene disorders, the pathogenic mutation locations from both parents must be provided; otherwise, linkage analysis cannot be performed.
• The data analysis software in Georgian laboratories is often in English, and some institutions lack local genetic counseling services, leading to difficulties in report interpretation. Users might receive an Excel file they cannot understand at all.

6. Differences Between Countries: Georgia vs. Ukraine vs. USA vs. China

Choosing which country to undergo NGS whole genome sequencing requires considering the following aspects:

Georgia's advantages lie in its low cost and simplified process (usually no medical indication required for application), but users must bear a higher risk of report interpretation.

7. Actual Process: What to Prepare for NGS Whole Genome Sequencing in Georgia?

Assuming you have decided to undergo IVF + NGS whole genome sequencing at a reproductive center in Georgia, the specific steps are:

1. Preliminary Assessment: Both partners undergo peripheral blood karyotyping and carrier screening (if a single-gene disorder is known, provide the specific gene name and mutation site).
2. Ovarian Stimulation and Egg Retrieval: Standard procedure, lasting approximately 10-14 days.
3. In Vitro Fertilization and Blastocyst Culture: Usually cultured to Day 5-6 blastocysts; biopsy is only performed when the blastocyst reaches the expanded stage (≥4BB).
4. Embryo Biopsy: A hole is made in the zona pellucida, and 3-10 trophectoderm cells are aspirated.
5. Whole Genome Amplification and Library Construction: Takes about 8-12 hours. The sample is then sent to a local or partner third-party sequencing company in Georgia (some centers need to mail samples to laboratories in Tbilisi or Moscow).
6. Sequencing and Analysis: Data output takes 2-5 days, producing a report including chromosome copy number variations, large deletions/duplications, and selected single-gene loci.
7. Report Interpretation and Embryo Selection: The reproductive doctor, combined with embryo morphological grading, recommends normal embryos for transfer. If all embryos are abnormal, the cycle proceeds to the next attempt or considers egg/sperm donation.

The entire additional testing process generally requires an extra stay of 7-10 days. If returning after egg freezing, 1-2 round trips need to be arranged in advance.

8. Frequently Asked Questions and Answers

Q: Can NGS whole genome sequencing in Georgia detect Down syndrome?
A: Yes. NGS has extremely high sensitivity for trisomy 21, detecting it almost 100% of the time.

Q: I saw online that some people get a "variant of uncertain significance (VOUS)" result after whole genome sequencing. What should I do?
A: VOUS is a common finding in genetic testing (incidence about 5%-15%). In Georgia, most centers will require confirmatory site-specific PCR from both parents, at an additional cost. If it cannot be verified, the embryo is generally not recommended for transfer.

Q: Is NGS technology in Georgia better than PGT-A?
A: NGS whole genome sequencing has superior resolution compared to traditional PGT-A (which usually only analyzes chromosomal ploidy changes), but it increases time and cost and involves more complex interpretation of mosaicism. For simple age-related chromosomal aneuploidy screening, PGT-A is sufficient. Whole genome sequencing is more suitable when there are clear structural abnormalities or single-gene disorders.

Q: Does whole genome sequencing affect embryo implantation rates?
A: Standard blastocyst biopsy has no significant negative impact on implantation rates (literature shows a decrease of approximately 0-5% after biopsy). However, the key is the laboratory's biopsy technique; if the inner cell mass is damaged during biopsy, it may reduce pregnancy potential. It is recommended to choose a center performing over 200 biopsies daily.

9. Risk Reminders

Before deciding to utilize Georgia's NGS whole genome sequencing technology, please be sure to verify the following three points:

• Confirm Laboratory Qualifications: Request external quality assessment reports from the last 6 months (e.g., CAP, JGCL, or international third-party blind test results).
• Clarify Report Turnaround Time: Some sequencing companies take 7-10 working days to issue reports, which may necessitate a second round of embryo freezing, potentially affecting survival rates.
• Budget for Genetic Counseling: Even if the testing cost is low, if the report shows VOUS or mosaicism, additional verification and counseling costs can reach 30%-50% of the testing fee.

Georgia's NGS whole genome sequencing offers clear advantages in price and convenience, but it is not a "one-size-fits-all" solution. Each embryo biopsy only represents a portion of the blastocyst's cells and cannot rule out postnatal epigenetic changes or maternal factors leading to miscarriage. It is recommended to use it as an auxiliary decision-making tool, not the sole criterion.